Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd
  6. Phase I

Phase I

Evaluate

Thumbnail
July 27, 2023

Roche loses more of its Spark

Thumbnail
July 25, 2023

Dravet efficacy wanes for Stoke

Article image
Vantage logo
July 21, 2023

Tau lags amyloid, but Bristol Myers sees potential

Article image
Vantage logo
July 18, 2023

AAIC 2023 – Acumen’s new amyloid approach impresses

But how different is ACU193 really?

Article image
Vantage logo
July 03, 2023

Big readouts ahead for small biotechs

Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.

Article image
Vantage logo
July 03, 2023

Zealand’s amylin is promising, but way behind Novo’s combo

Article image
Vantage logo
June 28, 2023

Black Diamond’s lung cancer pivot delivers

The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?

Article image
Vantage logo
June 23, 2023

Easl 2023 – GLP-1 combos take on a milder form of Nash

Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.

Article image
Vantage logo
June 15, 2023

Lilly signs up Verve to take on Novartis and Amgen

Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.

Article image
Vantage logo
June 13, 2023

Hope springs for April inhibition

Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.

Article image
Vantage logo
June 08, 2023

Aerow hits the mark for 4D Molecular

An early success with its cystic fibrosis gene therapy brings the company up.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up